Clinical Trials Sponsored by Point Therapeutics

Total 6593 results

Point Therapeutics

Completed

Study of Talabostat and Docetaxel in Advanced Non-Small Cell Lung Cancer

Lung Cancer

United States
Point Therapeutics

Terminated

Study of Talabostat and Pemetrexed vs. Pemetrexed in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy

Carcinoma, Non-Small-Cell Lung | Lung Cancer | Neoplasms, Lung | Neoplasms, Pulmonary

United States
Point Therapeutics

Terminated

Study of Talabostat + Docetaxel Versus Docetaxel in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy

Carcinoma, Non-Small Cell Lung

United States
Point Therapeutics

Terminated

Trial of Talabostat and Gemcitabine in Patients With Stage IV Adenocarcinoma of the Pancreas

Adenocarcinoma | Neoplasm Metastasis | Pancreatic Cancer

United States
Point Therapeutics

Completed

Study of Talabostat and Cisplatin in Advanced Melanoma

Melanoma | Skin Cancer

United States
Point Therapeutics

Completed

Study of Talabostat in Advanced Melanoma

Melanoma | Skin Cancer

United States
Zero Point Five Therapeutics

Not yet recruiting

Phase 3, Multi-center, Prospective, Randomized, Double-blind, Placebo- Controlled Study to Evaluate the Effectiveness and Safety of ZP5-9676 for the Treatment of Soil Transmitted Helminthiasis (STH)

Soil-Transmitted Helminthiasis (STH)

Brazil, Ghana
Turning Point Therapeutics, Inc.

Recruiting

A Phase 1 Study to Evaluate the Potential Drug Interactions Between Repotrectinib and Metformin, Digoxin, and Rosuvastatin in Patients With Advanced Solid Tumors

Advanced Solid Tumor | Metastatic Solid Tumor

United States
Turning Point Therapeutics, Inc.

Withdrawn

A Phase 1 Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of Repotrectinib in Advanced Cancer Patients

Metastatic Solid Tumor | Locally Advanced Solid Tumor

United States, Spain
Turning Point Therapeutics, Inc.

Terminated

Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations

Non Small Cell Lung Cancer | Advanced Solid Tumor | Metastatic Solid Tumor | Medullary Thyroid Cancer | RET Gene Mutation

United States, Korea, Republic of
Turning Point Therapeutics, Inc.

Terminated

A Study of TPX-0131, a Novel Oral ALK Tyrosine Kinase Inhibitor, in Patients With ALK+ Advanced or Metastatic NSCLC

Non-Small Cell Lung Cancer | NSCLC | Non Small Cell Lung Cancer | Advanced Solid Tumor | Metastatic Solid Tumor | ALK Gene Mutation

United States, Australia, Korea, Republic of
Turning Point Therapeutics, Inc.

Recruiting

A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

Lymphoma | Locally Advanced Solid Tumors | Metastatic Solid Tumors | Primary CNS Tumors

United States, Korea, Republic of, Spain, Singapore, Taiwan, Australia, Italy, Canada, France, Denmark, United Kingdom
Turning Point Therapeutics, Inc.

Completed

Study of Turning Point Therapeutics LM-302 in Patients With Advance Solid Tumors

Advanced Solid Tumor

United States
Turning Point Therapeutics, Inc.

Terminated

A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors

Advanced Solid Tumor | Metastatic Solid Tumor | KRAS Mutation-Related Tumors

United States
Turning Point Therapeutics, Inc.

Active, not recruiting

Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET (SHIELD-1)

Advanced Solid Tumor | Metastatic Solid Tumors | MET Gene Alterations

United States, France, Korea, Democratic People's Republic of, Korea, Republic of, Spain
Pain Therapeutics

Completed

Effects of Ethanol on Oxycodone Pharmacokinetics in Healthy Volunteers

Healthy

United States
Pain Therapeutics

Completed

Dose Proportionality Study Of PF-00345439 Formulation Under Fed Conditions

Healthy

United States
Pain Therapeutics

Completed

Abuse Potential Study of PF-00345439

Opioid Users

United States
Pain Therapeutics

Completed

Pharmacokinetics And Relative Bioavailability Study Of Oxycodone

Pain

Singapore
Pain Therapeutics

Completed

Food Effect And Relative Bioavailability Study Of Oxycodone in Healthy Volunteers

Healthy

United States
Pain Therapeutics

Completed

A Study To Characterize The Pharmacokinetics Of Oxycodone In Healthy Volunteers

Pain

United States
Pain Therapeutics

Completed

Single-Dose, Crossover Study To Compare Bioavailability Of Two Formulations Under Fed And Fasted Conditions

Healthy

United States
Pain Therapeutics

Completed

Dose Escalation and Safety Study of 188Re-PTI-6D2 in Patients With Metastatic Melanoma

Metastatic Melanoma

Israel
Pain Therapeutics

Completed

Study to Evaluate the Subjective Effects of PTI-801 in Non-Physically Dependent Subjects With a History of Drug Abuse

Opioid-Related Disorders

United States
Pain Therapeutics

Completed

Effects of Food on Oxycodone Pharmacokinetics in Healthy Volunteers

Healthy

United States
Pain Therapeutics

Completed

Long-term Safety of PF-00345439 (Oxycodone)

Pain
Pain Therapeutics

Completed

Pharmacokinetics And Relative Bioavailability Study Of Oxycodone in Healthy Volunteers

Healthy

United States
Pain Therapeutics

Completed

Safety Study of 188Re-PTI-6D2 in Patients With Metastatic Melanoma

Metastatic Melanoma

Israel
High Point Clinical Trials Center
Ferox Therapeutics

Terminated

Insulin Tolerance Test Study in Patients With Type 1 Diabetes

Hypoglycemia | Type 1 Diabetes

United States
Instituto Oncológico Dr Rosell
Turning Point Therapeutics, Inc.

Recruiting

Phase I Study of Repotrectinib and Osimertinib in NSCLC Patients (TOTEM)

Nsclc

Spain
Point Therapeutics

Completed

Study of Talabostat and Rituximab in Advanced Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia

United States
Pain Therapeutics
PRA Health Sciences

Completed

Nasal Human Abuse Potential of PTI-821

Opioid Abuse Nondependent

United States
Point Biomedical

Completed

Safety and Efficacy Study of PB127 Ultrasound Contrast Agent in Patients With Suspected Coronary Artery Disease

Coronary Artery Disease

United States
Point Biomedical

Completed

Familiarization and Safety Study of PB127 Ultrasound Contrast Agent

Coronary Artery Disease

United States
Point Biomedical

Terminated

Safety and Efficacy Study of PB127 Ultrasound Contrast Agent for Diagnosis of Coronary Artery Disease (POINT II)

Coronary Artery Disease

United States
Point Biomedical

Completed

Dose Finding Study of PB127 Ultrasound Contrast Agent in Healthy Volunteers and Patients With Coronary Artery Disease

Coronary Artery Disease | Healthy

United States
POINT Biopharma

Active, not recruiting

FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)

Soft Tissue Sarcoma | Colorectal Cancer | Esophageal Cancer | Cholangiocarcinoma | Head and Neck Squamous Cell Carcinoma | Pancreatic Ductal Adenocarcinoma | Melanoma (Skin)

United States, Canada
Point Biomedical

Completed

Safety and Efficacy Study of PB127 Ultrasound Contrast Agent in Patients With Suspected Coronary Artery Disease 007

Coronary Artery Disease

United States
Point Biomedical

Terminated

Long-Term Follow-up Study of Patients Who Received PB127 Ultrasound Imaging Agent

Coronary Artery Disease

United States
Point Biomedical

Terminated

Evaluation and Optimization of PB127 Myocardial Perfusion Echocardiography on Ultrasound Systems

Coronary Artery Disease | Healthy

United States
Turning Point Therapeutics, Inc.
Zai Lab (Shanghai) Co., Ltd.

Recruiting

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)

Locally Advanced Solid Tumors | Metastatic Solid Tumors

United States, China, Japan, Australia, Belgium, Canada, Denmark, France, Germany, Hong Kong, Hungary, Italy, Korea, Democratic People's Republic of, Korea, Republic of, Netherlands, Poland, Singapore, Spain, Taiwan, United Kingdom
High Point University

Recruiting

The Effect of Combining Pain Neuroscience Education and Transcranial Direct Current Stimulation on Pain Catastrophizing, Kinesiophobia, and Pain in Patients With Chronic Low Back Pain

Chronic Low-back Pain | Catastrophizing Pain | Kinesiophobia

United States
High Point University

Terminated

The Diagnostic Accuracy of the Clinical Examination

Musculoskeletal Pain | Musculoskeletal Injury

United States
High Point University

Completed

Real-time Optimized Biofeedback Utilizing Sport Techniques (ROBUST)

Knee Injuries
High Point University

Completed

Utilizing the Trunk as a Proximal Lever to Strengthen the Hip Musculature and Alter Lower Extremity Function

Patellofemoral Pain Syndrome

United States
High Point University

Completed

Conservative Management of Femoroacetabular Impingement

Femoroacetabular Impingement

United States
High Point University

Completed

Do Common Physical Tests Predict Injury or Performance (TEAM)

Lower Extremity Musculoskeletal Injury

United States
Cell>Point LLC

Completed

A Single Center Study to Establish the Imaging Protocol of 99mTc-EC-DG in Evaluating the Presence and Severity of Coronary Artery Disease (CAD)

Coronary Artery Disease

United States
Cell>Point LLC

Unknown

Efficacy and Saftey Study of 99mTc-ECDG in the Evaluation of Coronary Artery Disease (CAD)

Coronary Artery Disease

United States
Cell>Point LLC

Active, not recruiting

A Phase 3 Study of 99mTC-EC-DG SPECT/CT Versus PET/CT in Lung Cancer

Lung Cancer

United States

Clinical Trials Sponsored by Point Therapeutics

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mali

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations